Today the pharmacological possibilities of treating cancer are expanding and as a result, life
expectancy is increasing against the background of chemotherapy and supportive treatment …

Diabetes mellitus is a common disorder of endocrine and metabolic disorders. Long term
hyperglycemia can lead to a variety of serious chronic complications, such as diabetic …

Doxorubicin is a commonly used anticancer agent that can cause debilitating and
irreversible cardiac injury. The initiating mechanisms contributing to this side effect remain …

Myocardial infarction (MI), the main cause of cardiovascular-related deaths worldwide, has
long been a hot topic because of its threat to public health. S100A8/A9 has recently attracted …

An excessive neutrophil count is recognized as a valuable predictor of inflammation and is
associated with a higher risk of adverse cardiac events in patients with heart failure. Our …

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases.
In addition, several studies indicate that MetS correlates with the increased risk of cancer in …

Doxorubicin (DOX)‐induced cardiotoxicity limits its broad use as a chemotherapy agent. The
development of effective and non‐invasive strategies to prevent DOX‐associated adverse …

Rationale: Calcium channel blockers (CCBs) are an important class of drugs in managing
cardiovascular diseases. Patients usually rely on these medications for the remainder of …

Despite the availability of several effective and promising treatment methods, heart failure
(HF) remains a significant public health concern that requires advanced therapeutic …

Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …